CPT-11 transarterial chemoembolization prolongs survival of patients with unresectable hepatocellular carcinoma
10.3760/cma.j.issn.1007-631X.2014.07.015
- VernacularTitle:伊立替康经肝动脉栓塞化疗对不可切除肝癌患者生存期的影响
- Author:
Jie WU
;
Lei SONG
;
Danyi ZHAO
;
Jing LIU
;
Bing GUO
- Publication Type:Journal Article
- Keywords:
Carcinoma,hepatocellular;
Chemoembolization therapeutic;
Antineoplastic combined chemotherapy protocols;
Survival rate;
Irinotecan
- From:
Chinese Journal of General Surgery
2014;29(7):534-537
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the efficacy of CPT-11 TACE in the treatment of unresectable HCC.Methods A retrospective review was undertaken on unresectable HCC patients receiving doxorubicin transarterial chemoembolization (59 cases) and irinotecan(CPT-11) in 24 cases from May 2003 to November 2011.Survival analysis was performed with Kaplan-Meier statistics.Differences in survival between the two groups were assessed for statistical significance with the log-rank test.Results Overall survival time was significantly longer in patients treated with CPT-11 compared with doxorubicin treated group (21.7 vs 14.5 months,P =0.042).There was no significant difference in time to progression between the two groups,but time to progression was longer in CPT-11 group than doxorubicin treated group (11.42 vs 9.46 months,P =0.091).Subgroup analysis showed that for intermediate-stage HCC,CPT-11 resulted in a significantly longer time to progression and overall survival compared with doxorubicin treated group (P =0.029 and P =0.014,respectively).There were no significant differences in adverse events among the two groups (P ＞ 0.05).Conclusions Chemotherapeutic agent CPT-11 in the form of TACE significantly improved overall survival when compared with doxorubicin for the treatment of unresectable HCC.
